They had another 1 on 1 meeting with institutional investor. Having not done/postponed earnings call, they seem to be communicating very little with retail investor. Though the results have been terrific.
Any idea what could be the reason ? Mostly when companies do well they talk more. Also, i have owned this stock for 6 months, were they historically poor communicator?
Someone in a moneycontrol blog mentioned that GST for contraceptives is now zero.
Can anyone throw light on what it was before GST ?
What was earlier tax rate?
Pisitive development at Cupid…Chief Business Development Officer appointed…Samir Prasad having good experience https://www.google.com.kw/url?sa=t&source=web&rct=j&url=https://www.cupidltd.in/wp-content/uploads/2017/04/27_Press_BSE.pdf&ved=0ahUKEwin0t_DhPzTAhXBDxoKHX6dBh4QFggkMAI&usg=AFQjCNG3KRgqua5EdZmTBou-xMMOWmBbhA&sig2=CV--e7oVM4ipHHJE4gVmXQ
Another good point…A well known FII Wasatch Advisors Inc purchased more than 200000 shares of cupid in Apri and May
I think currently also it is exempted from the VAT. So, there should not any effect of this …
Improving communication: Investors’ conference call on 25th May 2017
http://www.bseindia.com/corporates/anndet_new.aspx?newsid=ce41d1ea-5d8c-4bfa-9db3-b4b8239a920c
Hope someone finds an answer to the usability issues to the product in the concall. After my initial excitement i realised that the product was not very usable based on asking many doctors and fellow colleagues. Hence i have exited the position until clarity emerges.
Cupid Press Release - Sales growth 36% and PAT growth 29% over FY16 Declared Rs 2 Dividend!
As on 31st March 2017 - confirmed order of Rs 580 mn and repeat order of Rs 310 mn both executable in coming period. Company having good growth vision.
http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/ca76524c-ffa7-4009-9653-e56dd3f656ef.pdf
Reserves+surplus - almost double , no increase in trade receivables, no increase in inventory, almost double in cash and cash equivalent, zero long term and Zero short term borrowing (secured)…excellent balance sheet
http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/91c128e3-b1a3-4c8c-9ff6-8b75bb26966b.pdf
Disc - Invested in cupid
Optically, YoY, the results look good, but this quarter results were a bit below expectations (Mr Garg had indirectly guided for around 20 cr sales, but only 17.8 cr was achieved).
No evidence of the lubricant jelly orders ramping up yet .
No new visibility of the order book ( it seems to have remained the same , which is bad)
In short, we might have to wait a while for Cupid to get re-rated .
However, the silver lining is that management commentary looks optimistic .
The next two quarters might provide an insight whether the next growth trajectory is commenced or not 
Although YoY results look good, the Q4 results are muted with very flat numbers. Operating income has 1% increase compared to Q4 FY-16.
Water base lubricant seems to be going steadily athough still very small part of overall product portfolio.
Market has reacted negatively, My thinking is compnay need to deliver 20%+ topline growth to sustain the valuation.
Disc- Invested.
Poor results. The pipeline for next year look similar to this year revenue, so growth could be flat. Not sure if diversification is yielding results but core growth commentary is to be watched carefully. the stock was not doing anything in last quarter with little management communication, cancellation of last quarter concall, one to one calls with institutional buyers and selling/moving of promoter stake.
Disc: exited major position still with small exposure.
Interesting article on Indian market for those who are invested and interested in Cupid
Could anyone who attend the Cupid Conference call post their key takeaways?
Key Takeaways from Q4 Concall as per mgmt. guidance:
Personally, I feel this year Change in Mgmt + Acquisition plan + USFDA approval for FC (in Oct 2016 concall said 12-18 months for approval i.e. expected by Q4 FY 18 or Q1 FY 19) + Sales & Marketing skills on execution seen on ground & online are triggers to be seen.
Acceptability & ease of use in FC can be validated only by success of mass retail strategy which is a tough ask and demands a dynamic team( as behavioral / buying process requires change in FC). For opportunity size to grow for this company, product & geographical diversification seems to be a better bet, considering FHC is already in biz since 1993. I feel existing business in FC can only propel biz soo far as it will attract competitors in this high margin B2B biz in future. Hence, introducing new high margin value added products can ensure sustainability of profits.
Please add/correct/contribute to above.
P.S: Invested, views may be biased.
Well Summarized. Thanks.
Any idea why there was less revenue booked this quarter both QoQ and YoY, cause they had pipeline and also capacity ?
I think this would mean short term pain for financials and wait/hope for investors that management would be able to execute all these strategies. I think management is spreading itself too thin too fast. More so considering limited bench strength and management bandwidth as of now. So biggest risk is focused business delivering great return can easily become de-focused low return business.
Disclosure - Sold all shares before QIP. Watching with interest
Thanks for the update. Did management comment upon the renewal of SA order? Last I remember they said it would be 50% more than the last time
